CUDC-101
- Generic Name
- CUDC-101
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N4O4
- CAS Number
- 1012054-59-9
- Unique Ingredient Identifier
- 1A7Y9MP123
- Background
CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT01702285
- Locations
- ๐บ๐ธ
Southern Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
๐บ๐ธKarmanos Cancer Institute, Detroit, Michigan, United States
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
- Conditions
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01384799
- Locations
- ๐บ๐ธ
Vanderbilt University, Nashville, Tennessee, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
- Conditions
- Interventions
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01171924
- Locations
- ๐บ๐ธ
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
๐บ๐ธMountain Blue Global Cancer Care, Wheat Ridge, Colorado, United States
๐บ๐ธSan Diego Pacific Oncology and Hematology Associates, Encinitas, California, United States
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00728793
- Locations
- ๐บ๐ธ
Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธSTART (South Texas Accelerated Research Therapeutics), San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.